as its use increases. Fauroux et al. 5 demonstrated the improved efficacy of sedation, pain control, and safety of premixed 50% nitrous oxide and oxygen for fiberoptic bronchoscopy in children.
In a small series of extremely low birth weight infants, the surviving infants received norepinephrine and epinephrine in a dosage < 0.6 g/kg/minute prior to arginine-vasopressin medication. We have just ended our second study, a double-blind, randomized controlled trial that assessed the use of low-dose vasopressin in children with severe respiratory disease. We want to extend our appreciation to the writer for sharing his own experience with the use of arginine-vasopressin in preterm neonates.
